DOAJ Open Access 2025

SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology

Marlena Stielow Łukasz Fijałkowski Aidas Alaburda Grzegorz Grześk Elżbieta Grześk +2 lainnya

Abstrak

Studies have shown that sodium-glucose cotransporter type 2 (SGLT2) inhibitors not only help lower blood glucose levels but also offer cardioprotective effects, reduce the progression of heart failure, and may even slow the progression of aortic stenosis. The mechanisms of these beneficial properties are thought to involve multiple pathways, including reducing inflammation, oxidative stress, and improving cellular energy metabolism. Advancing knowledge about the mechanisms of action of these drugs and their effects on the course of the aforementioned diseases has become the subject of intensive clinical and scientific research. This publication aims to provide insight into the role of SGLT2 inhibitors in the context of diabetes mellitus, heart failure and acute coronary syndrome, through clinical analysis, mechanistic insights and comparison of the effects of these drugs.

Topik & Kata Kunci

Organic chemistry

Penulis (7)

Marlena Stielow

Łukasz Fijałkowski

Aidas Alaburda

Grzegorz Grześk

Elżbieta Grześk

Jacek Nowaczyk

Alicja Nowaczyk

Format Sitasi

APA MLA BibTeX

Stielow, M., Fijałkowski, Ł., Alaburda, A., Grześk, G., Grześk, E., Nowaczyk, J. et al. (2025). SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology. https://doi.org/10.3390/molecules30153112

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →

Lihat di Sumber doi.org/10.3390/molecules30153112

Informasi Jurnal

Tahun Terbit: 2025
Sumber Database: DOAJ
DOI: 10.3390/molecules30153112
Akses: Open Access ✓